SCHEMBL35210773

SCHEMBL35210773

O=c1c2ccccc2ccn1-c1nccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.51
MAPT P10636 7/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
G6PD P11413 1/20 0.51
PKM P14618 1/20 0.51
MPI P34949 1/20 0.51
EP300 Q09472 1/20 0.51
KAT2A Q92830 1/20 0.51
KAT2B Q92831 1/20 0.51
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
NPSR1 Q6W5P4 3/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.43
GLA P06280 1/20 0.43
SLC11A2 P49281 1/20 0.40
POLB P06746 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706154 0.78 LMNA (0.47) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL31362935 0.73 ALDH1A1 (0.35) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL28557365 0.73 GAA (0.51) KDM4EMAPTALDH1A1GAAEP300
SCHEMBL16794591 0.73 LMNA (0.54) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL29962872 0.73 GAA (0.51) KDM4EMAPTALDH1A1GAAEP300
SCHEMBL5579491 0.72 LMNA (0.53) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL5820389 0.72 LMNA (0.42) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL26544755 0.72 LMNA (0.53) KDM4EMAPTALDH1A1GAATDP1
SCHEMBL14912462 0.71 MEN1 (0.43) KDM4EMAPTALDH1A1KMT2AMEN1
SCHEMBL20688413 0.71 LMNA (0.41) KDM4EMAPTALDH1A1GAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125346-A1 Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125346-A1 Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease NR3C1, NR3C2, PIK3R4 KDM4E 3237/4885MAPT 1022/4885ALDH1A1 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.